<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2582">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127551</url>
  </required_header>
  <id_info>
    <org_study_id>INFI-103-COMP</org_study_id>
    <nct_id>NCT05127551</nct_id>
  </id_info>
  <brief_title>Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor</brief_title>
  <official_title>A Prospective, Randomized, Controlled, Comparitive Multicenter Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite® vs Competitor in Adult Subjects With Primary Open-Angle Glaucoma (POAG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of the iStent Infinite product in the treatment of open-angle glaucoma vs competitor&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Submitted in error&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Diurnal Intraocular Pressure</measure>
    <time_frame>Month 24</time_frame>
    <description>Change in Mean Diurnal Intraocular Pressure from Baseline over time</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Glaucoma</condition>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>iStent Infinite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects implanted with iStent Infinite system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Competitor Device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject implanted with competitor device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent Infinite</intervention_name>
    <description>Implantation of the iStent Infinite</description>
    <arm_group_label>iStent Infinite</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Competitor Device</intervention_name>
    <description>Implantation of competitor device</description>
    <arm_group_label>Competitor Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Primary Open-Angle Glaucoma (POAG) or Secondary Pseudoexfoliative Glacoma&#xD;
             (PEXG) or Secondary Pigmentary Glaucoma (PG)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other type of glaucoma including, but not limited to: traumatic glaucoma, angle&#xD;
             recession glaucoma, uveitic glaucoma, neovascular glaucoma, angle closure glaucoma&#xD;
             (ACG) and glaucoma associated with vascular disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>MIGS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

